Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer.

Biochemical pharmacology - 1 Jun 2021

Liu Xi, Hu Qian, Wang Wanyan, Ma Hui, Pu Jiaqian, Cui Jiayan, Gong Ting, Wu Yu, Lu Weiqiang, Huang Jin

Abstract excerpt

Somatic gain-of-function mutations within estrogen receptor alpha (ERα) are highly associated with hormone therapy resistance in breast cancer. However, current understanding of abnormal activity of ERα mutants and their relevant targeted intervention is still very limited. Herein, we developed a new, real-time, and reliably Gaussia luciferase-based protein-fragment complementation assay (GLPCA) for evaluating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to HEK293 Cells

Share to MCF-7 Cells

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Protein Structure, Secondary

Source

Identifiers

PMID: 33915156
DOI: 10.1016/j.bcp.2021.114583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer.PMID 33915156Read ↗

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.Semantic proximity Read ↗

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.Semantic proximity Read ↗

A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degraderSemantic proximity Read ↗

Non-invasive imaging of estrogen receptor-coregulator interaction by luciferase fragment complementationSemantic proximity Read ↗

A simple and robust reporter-based framework for deep functional characterization of PPARγ mutants.Semantic proximity Read ↗

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.Semantic proximity Read ↗

A highly efficient and sensitive screening method for trans-activation activity of estrogen receptors.Semantic proximity Read ↗

Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.Semantic proximity Read ↗

Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.Semantic proximity Read ↗

Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.Semantic proximity Read ↗

Discovery, synthesis, activities, structure–activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive reviewSemantic proximity Read ↗

A human estrogen receptor (ER)alpha mutation with differential responsiveness to nonsteroidal ligands: novel approaches for studying mechanism of ER action.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.